Catherine Van Poznak

8PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Dec 20, 2023
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.

Hope S Rugo, Catherine H Van Poznak, Patrick Neven

|Jun 13, 2023
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).

Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso

|Dec 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.

Ghada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu

|Feb 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.

Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob

|Jan 18, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

Andrea Eisen, Mark R Somerfield, Melissa K Accordino

Pageof 2

Frequent Collaborators

4 joint publications

Kathryn Ruddy

3 joint publications

Minetta Liu

3 joint publications

Ann Partridge

3 joint publications

Antonio C Wolff